Responses
Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
518 Discovery of MACO-355, a novel, first in mechanism ligand-blocking independent anti-LILRB1/2 monoclonal antibody for cancer therapy
Compose a Response to This Article
Other responses
No responses have been published for this article.
